What Sparked AbCellera Biologics To Soar Over 9% After Hours

Benzinga02-25 16:51

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.

Earnings Beat Drives After-Hours Rally

Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.

AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.

Its revenue also increased by $39.80 million from a year earlier.

The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.

Trading Metrics, Technical Analysis

AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.

It has a Relative Strength Index (RSI) of 44.92.

The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.

Price Action: ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.

The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.

Benzinga's Edge Stock Rankings indicate that ABCL has a negative price trend across all time frames.

Photo courtesy: santima.studio / Shutterstock

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614701768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614701768","market":"us","top_or_hot":-1,"title":"What Sparked AbCellera Biologics To Soar Over 9% After Hours","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. </strong>(NASDAQ:ABCL) shares are trending on Wednesday.</p>\n<h2><strong>Earnings Beat Drives After-Hours Rally</strong></h2>\n<p>Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.</p>\n<p>AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.</p>\n<p>Its revenue also increased by $39.80 million from a year earlier.</p>\n<p>The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.</p>\n<h2>Trading Metrics, Technical Analysis</h2>\n<p>AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.</p>\n<p>It has a Relative Strength Index (RSI) of 44.92.</p>\n<p>The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.</p>\n<p><strong>Price Action: </strong>ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.</p>\n<p>The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.</p>\n<p><strong>Benzinga's Edge Stock Rankings</strong> indicate that ABCL has a negative price trend across all time frames.</p>\n<figure><img decoding=\"async\" height=\"265\" loading=\"lazy\" sizes=\"(max-width: 432px) 100vw, 432px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587-300x184.png 300w\" width=\"432\"/></figure>\n<p><em>Photo courtesy: santima.studio / Shutterstock</em></p>\n<p><strong>Disclaimer:</strong> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Sparked AbCellera Biologics To Soar Over 9% After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Sparked AbCellera Biologics To Soar Over 9% After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-02-25 16:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. </strong>(NASDAQ:ABCL) shares are trending on Wednesday.</p>\n<h2><strong>Earnings Beat Drives After-Hours Rally</strong></h2>\n<p>Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.</p>\n<p>AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.</p>\n<p>Its revenue also increased by $39.80 million from a year earlier.</p>\n<p>The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.</p>\n<h2>Trading Metrics, Technical Analysis</h2>\n<p>AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.</p>\n<p>It has a Relative Strength Index (RSI) of 44.92.</p>\n<p>The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.</p>\n<p><strong>Price Action: </strong>ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.</p>\n<p>The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.</p>\n<p><strong>Benzinga's Edge Stock Rankings</strong> indicate that ABCL has a negative price trend across all time frames.</p>\n<figure><img decoding=\"async\" height=\"265\" loading=\"lazy\" sizes=\"(max-width: 432px) 100vw, 432px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587-300x184.png 300w\" width=\"432\"/></figure>\n<p><em>Photo courtesy: santima.studio / Shutterstock</em></p>\n<p><strong>Disclaimer:</strong> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/02/50841437/what-sparked-abcellera-biologics-to-soar-over-9-after-hours","article_id":"2614701768","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614701768","pubTimestamp":1772009491,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务","ABCL":"AbCellera Biologics","RSI":"Rush Street Interactive, Inc.","BK4150":"赌场与赌博"},"translate_title":"是什么引发AbCellera Biologics盘后飙升超过9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSI":1,"ABCL":1.5},"content_text":"AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.\nEarnings Beat Drives After-Hours Rally\nShares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.\nAbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.\nIts revenue also increased by $39.80 million from a year earlier.\nThe fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.\nTrading Metrics, Technical Analysis\nAbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.\nIt has a Relative Strength Index (RSI) of 44.92.\nThe stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.\nPrice Action: ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.\nThe stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.\nBenzinga's Edge Stock Rankings indicate that ABCL has a negative price trend across all time frames.\n\nPhoto courtesy: santima.studio / Shutterstock\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614701768","isCrawlerRequest":true}